<DOC>
	<DOCNO>NCT00948064</DOCNO>
	<brief_summary>The goal clinical research study learn combination azacitidine vorinostat help control AML MDS good azacitidine alone . The safety drug combination also study .</brief_summary>
	<brief_title>Vorinostat Combination With Azacitidine Patients With Newly-Diagnosed Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The Study Drugs : Azacitidine design block certain gene cancer cell whose job stop function tumor-fighting gene . By block `` bad '' gene , tumor-fighting gene may able work well . Vorinostat design cause chemical change different group protein attach DNA ( genetic material cell ) , may slow growth cancer cell cause cancer cell die . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 group . - If Group 1 , receive azacitidine vorinostat . - If Group 2 , receive azacitidine alone . For first 40 patient , equal chance either group . After first 40 patient , high chance assign group base result previous participant . Study Drug Administration : On Days 1-5 every cycle , receive azacitidine vein 15-30 minute . If Group 1 , also take vorinostat mouth 3 time day food Days 1-5 every cycle . If take vorinostat mouth cycle , receive azacitidine cycle . You begin take vorinostat mouth able . Your dose study drug may lower experience side effect . You may receive drug ondansetron dose azacitidine prevent nausea vomit . If diarrhea , take drug Imodium ( loperamide ) prevent diarrhea . Study Visits : Once week Cycle 1 , follow test procedure perform : - Your complete medical history record . - You physical exam . - You ask experienced intolerable side effect . - Blood ( 1-2 tablespoon ) draw routine test . On Day 28 Cycle 1 ( +/- 3 day ) , bone marrow aspiration check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . If doctor think need , extra bone marrow aspiration later cycle check status disease . One ( 1 ) time cycle Cycles 2 beyond , follow test procedure perform : - Your complete medical history record . - You physical exam . - You ask experienced intolerable side effect . - If doctor think need , blood ( 2 tablespoon ) draw routine test . Length Study : You active study 12 cycle ( 12-18 month ) . You take study disease get bad experience intolerable side effect . This investigational study . Vorinostat FDA approve commercially available treatment cutaneous T-cell lymphoma . Azacitidine FDA approve commercially available treatment MDS . The combination drug use patient intermediate-1 high risk MDS AML investigational . Up 80 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . Patients newly diagnose AML MDS ( Intermediate 1 high risk ) 2 . Patient must least one following : a. Creatinine &gt; /= 2 mg/dL ; b. total Bilirubin &gt; /= 2 mg/dL ; c.ECOG Performance Status equal 3 4 ; d. ineligible participation protocol high priority 3 . Patients must provide write informed consent . 4 . Patients must age &gt; 18 year due lack safety information agent child . 5 . Patient agrees : 1 ) Use 2 adequate method contraception prevent pregnancy ( either 2 barrier method barrier method plus hormonal contraceptive method ) 2 ) abstain heterosexual activity throughout study start Visit 1 . 6 . Female patient childbearing potential negative pregnancy test ( serum ) within 72 hr . study enrollment . 1 . Patients must favorable cytogenetic abnormality inv ( 16 ) , ( 16 ; 16 ) , ( 8 ; 21 ) , ( 15 ; 17 ) . 2 . Patients receive antileukemic therapy exception Hydroxyurea prior study enrollment . Prior growth factor therapy acceptable . Hydroxyurea could use discretion treat physician . A single two day dose cytarabine ( 3 g/m^2 ) emergency use allow prior therapy . 3 . Patient prior history treatment HDAC inhibitor . Patients receive valproic acid ( VPA ) treatment seizure may enrol study , must receive VPA within 30 day study enrollment . 4 . Patient unable take and/or tolerate oral medication continuous basis , example include patient ventilator , alter mental status precludes safe oral route administration . 5 . Patient active hepatitis A , B , C infection . 6 . Patient pregnant breastfeeding . 7 . Patient know allergy hypersensitivity component vorinostat azacitidine . 8 . History psychiatric condition might impair patient 's ability understand comply requirement study provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-Azacitidine</keyword>
	<keyword>5-Aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
</DOC>